Guardant Health, Inc. filed an 8-K on November 16, 2026, disclosing the completion of a private offering of $550 million aggregate principal amount of 0% Convertible Senior Notes due 2032, including full exercise of the initial purchasers' overallotment option.
Key Highlights
- Total offering size: $550 million aggregate principal amount of 0% Convertible Senior Notes due 2032, including $50 million from full exercise of the overallotment option.
- Zero coupon: The Notes do not bear regular interest and the principal amount does not accrete, according to the filing.
- Maturity date: May 15, 2032, unless earlier converted, redeemed, or repurchased.
- Initial conversion price: Approximately $208.95 per share, representing a premium of approximately 35.0% above the last reported sale price of $154.78 per share on November 11, 2026.
- Conversion rate: 4.7858 shares of common stock per $1,000 principal amount of Notes.
- Optional redemption window: The company may redeem the Notes, subject to conditions, on or after November 20, 2029 and on or before the 25th scheduled trading day before maturity.
- Trustee: U.S. Bank Trust Company, National Association serves as trustee under the Indenture dated November 16, 2026.
Guardant Health Completes $550 Million Convertible Notes Offering Under 2026 Indenture
According to the 8-K filed with the Securities and Exchange Commission on November 16, 2026, Guardant Health, Inc. (NASDAQ:GH) completed a previously announced private offering of $550 million in aggregate principal amount of 0% Convertible Senior Notes due 2032. The filing states that the total includes the exercise in full of the initial purchasers' option to purchase up to an additional $50 million principal amount of Notes. The Notes were issued under an Indenture dated November 16, 2026, between the company and U.S. Bank Trust Company, National Association, as trustee.
The filing describes the Notes as senior, unsecured obligations that mature on May 15, 2032. The Notes carry no regular interest, and the principal amount does not accrete. The initial conversion rate is 4.7858 shares of common stock per $1,000 principal amount, equating to an initial conversion price of approximately $208.95 per share. The filing notes this conversion price represents a premium of approximately 35.0% above the last reported sale price of $154.78 per share on November 11, 2026. The company disclosed it will settle conversions in cash, shares of common stock, or a combination, at its election.
Noteholders may convert their Notes only under specified circumstances outlined in the Indenture, including if the common stock price exceeds 130% of the conversion price for at least 20 trading days during a specified 30-day window, or upon certain corporate events. The company may not redeem the Notes before November 20, 2029, except for a "cleanup redemption" as defined in the Indenture, which applies when the aggregate outstanding principal amount is less than $50.0 million and the Notes are "freely tradable." For a provisional redemption, the filing states the company may not redeem less than all outstanding Notes unless at least $100.0 million in aggregate principal amount remains outstanding and is not subject to redemption. The Indenture also includes customary covenants and events of default, including a cross-default threshold for indebtedness exceeding $150.0 million.
What Was Disclosed
Guardant Health disclosed the completion of a $550 million private offering of 0% Convertible Senior Notes due May 15, 2032, including key terms of the Indenture such as the conversion rate, redemption conditions, and events of default.




Please wait processing your request...